All items in the Healthy Skepticism Library
All the 20545 items in the Healthy Skepticism Library are listed below in order of publication date with the most recent at the top. There are 100 items per page.
Page 175 of 206 pages ‹ First < 173 174 175 176 177 > Last ›
HSL643
Aldir RE, Jarjoura D, Phinney M, Poordad F, Gutierrez R, Marnejon T, Greifenstein E, Lappin J, Whittier FC.
Practicing and resident physician’s views on pharmaceutical companies.
J Contin Educ Health Prof 1996;16:25-32
HSL644
[No authors listed]
Pharmacists can sell data, college says
CMAJ 1996;154:1881
http://www.cma.ca/cmaj/vol-154/1881a-e.htm
HSL2039
Estes R.
Tyrany of the bottom line: Why corporations make good people do bad things.
San Francisco: Berrett-Koehler 1996
http://www.bkconnection.com/ProdDetails.asp?ID=1881052753&PG=1&Type=BL&PCS=BKP
HSL2068
Barlow J, Møller C.
A complaint is a gift. Using customer feedback as a strategic tool.
San Francisco: Berrett-Koehler 1996
http://www.bkconnection.com/ProdDetails.asp?ID=1881052818&PG=1&Type=RLMa&PCS=BKP
HSL2678
European Public Health Alliance
Commercial sponsorship and NGOs
European Public Health Alliance 1996;
HSL6616
Marketing the medicine: Striving for optimal therapy: the 1995-1996 annual report
Ottawa: Phamaceutical Manufacturers Association of Canada 1996
HSL6617
Prescription for trouble
Ontario Medical Review 1996;63:(6):66-67
HSL6618
Appel S.
Consumer product information affects us all: iii. pharmacist view
Australian Prescriber 1996;19:33
www.australianprescriber.com
HSL6619
Apple RD.
Vitamania
New Brunswick, New Jersey: Rutgers University Press 1996
HSL6621
Barnett AA.
FDA proposes easing of promotion rules
Lancet 1996;347:52
HSL6622
Barnett AA.
FDA warns Pfizer on sertraline marketing
Lancet 1996;348:469
HSL6623
Basara LR.
The impact of a direct-to-consumer prescription medication advertising campaign on new prescription volume
Drug Information Journal 1996;30:715-729
http://www.diahome.org/abstract/dj303634.pdf
HSL6624
Beales JH.
New uses for old drugs: Competitive strategies in the pharmaceutical industry
Washington, DC, USA: AEI Press 1996
HSL6625
Beary JF 3rd.
Pharmaceutical marketing has real and proven value: Characteristics of materials distributed by drug companies: four points of view
Journal of General Internal Medicine 1996;11:635-636
HSL6626
Bennett JR.
Altruism and the scientific congress
Lancet 1996;347:377-378
HSL6627
Bero LA, Rennie D.
Influences on the quality of published drug studies.
Int J Technol Assess Health Care 1996 Spr;12:(2):209-37
HSL6631
Boadway T.
Marketing physician prescribing data
Ontario Medical Review 1996;63:(10):18
HSL6633
Bosco C.
College of Pharmacists’ position on prescribing data raises OMA concerns
Ontario Medical Review 1996;63:(6):25-27
HSL6634
Bosco C.
OMA takes action on marketing of physician prescribing data: private industry sales raise ethical/legal concerns
Ontario Medical Review 1996;63:(4):32-33
HSL6635
Breimer L.
Advertisements for drugs used in disorders with a negative image never feature men
BMJ 1996;313:883
http://www.bmj.com/cgi/content/full/313/7061/883/b
HSL6636
Calfee JJ
The leverage principle in the FDA's regulation of information
Washington, DC, USA: AEI Press 1996
HSL6637
Gabe J, Bury M.
Anxious times: the benzodiazepine controversy and the fracturing of expert authority
New York: Oxford University Press 1996
HSL6638
Huston P, Moyer D.
Pharmaceutical company trials and the integrity of medical research
Lancet 1996;347:1628-1629
HSL6639
Huston P.
Violence sells
Canadian Medical Association Journal 1996;154:758
HSL6640
Kawachi I, Conrad P.
Medicalization and the pharmacological treatment of blood pressure
New York: Oxford University Press 1996
HSL6641
Lexchin J, Kawachi I.
The self-regulation of pharmaceutical marketing: initiatives for reform
New York: Oxford University Press 1996
HSL6642
Mintzes B, Hodgkin C.
The consumer movement: from single-issue campaigns to long-term reform
New York: Oxford University Press 1996
HSL6643
Pearce N.
Adverse reactions, social responses: a tale of two asthma mortality epidemics
New York: Oxford University Press 1996
HSL6644
Sawaya L.
“The reader is not an idiot—he is your doctor.” On advertising to physicians
Orleans, Canada: RETICULUM 1996
HSL6645
Schimm DS, Spece RG, Digregorio M.
Conflicts of interest in relationships between physicians and the pharmaceutical industry
New York: Oxford University Press 1996
HSL6647
Servier’s multiple misleading promotion
MaLAM Australian News 1996;4:(1):1-2
HSL6657
Beaufour-Ipsen claims Smecta “treats the symptoms” and optimises the use of oral rehydration therapy
MaLAM International News 1996;14:(4):1-2
HSL6658
MaLAM letter follow up—Wyeth-Ayerst’s promotion of Polymagma (attapulgite)
MaLAM International News 1996;14:(4):2
HSL8327
Roylance PJ, Adornato FA, Currie WJ, Taglieber U.
Problems in achieving a consistent worldwide product circular
Drug Information Journal 1996;30:(4):869-873
HSL8334
Erwin J, Britten N, Jones R.
Pharmacists and deregulation: case of H2 antagonists
Journal of Social and Administrative Pharmacy 1996;13:(3):150-158
HSL8341
Blumenthal M.
Milestones in pharmaceutical botany since 1960.
Pharm Hist 1996;38:(1):24-8
HSL8343
Sukkari SR, Sasich LD, Nicholls PJ.
Promoting therapeutic information to the medical staff: evidence-based formulary
Saudi Pharmaceutical Journal 1996;4:(1):48-55
HSL8348
Reinstein JA.
Marketing medicines for self-medication
Journal of Pharmaceutical Marketing Management 1996;10:(2-3):31-38
HSL8923
Towse A.
The UK pharmaceutical market: An overview
PharmacoEconomics 1996;10:14-25
HSL8924
Le Pen C.
Drug pricing and reimbursement in France. Towards a new model?
Pharmacoeconomics. 1996;10:(Suppl 2):26-36.
http://www.ncbi.nlm.nih.gov/pubmed/10163433
HSL9049
Davis P.
Contested Ground: Public Concern and Private Interest in the Regulation of Pharmaceuticals
Oxford: Oxford Univ Press 1996
http://www.oup.com/uk/catalogue/?ci=9780195091205
HSL9137
Schoffski O.
Consequences of implementing a drug budget for office-based physicians in Germany.
Pharmacoeconomics 1996;10:
HSL9144
Lipson DP, Basara LA.
Community pharmacists' perceptions of the pharmaceutical industry: drug company image study
Journal of Pharmaceutical Marketing Management 1996;11:(1):43-59
HSL9147
Katsanis LP.
Pharmaceutical marketing research: blueprint for the future
Journal of Pharmaceutical Marketing Management 1996;10:(4):251-267
HSL9148
Dutton JE, Reece MA.
Impact of current trends in health care on the pharmaceutical sales force of the future
Journal of Pharmaceutical Marketing Management 1996;10:(4):237-249
HSL9153
Bobula JD.
New era in pharmaceutical pricing
Journal of Research in Pharmaceutical Economics 1996;7:(1-2):89-99
HSL9154
Cohen KR.
Managed competition: implications for the U.S. pharmaceutical industry
Journal of Research in Pharmaceutical Economics 1996;7:(1-2):29-40
HSL9155
Rich SJ.
Managed competition and formulary decisions
Journal of Research in Pharmaceutical Economics 1996;7:(1-2):101-108
HSL9156
Kucukarslan S.
In search of an understanding of pharmaceutical prices
Journal of Research in Pharmaceutical Economics 1996;7:(1-2):73-88
HSL13259
Andaleeb S, Tallman R.
Relationship of physicians with pharmaceutical sales representatives and pharmaceutical companies
Health Marketing Quarterly 1996;13:(4):78-89
http://www.haworthpress.com/store/Toc_views.asp?sid=TEDU6HV2D51M9JKMG5EB1C3E9DV4DCU9&TOCName=J026v13n04%5FTOC&desc=Volume%3A%2013%20Issue%3A%204
HSL14283
Greenhalgh T.
MaLAM
BMJ 1996;312:(1):61
HSL20505
Shenfield G
Knowledge into action
Australian Prescriber 1996;19:(1):
HSL6614
Food and Drug Administration
Advertising and promotion; draft guidances
1995 Dec 6
HSL1620
de Vries TP, Henning RH, Hogerzeil HV, Bapna JS, Bero L, Kafle KK, Mabadeje A, Santoso B, Smith AJ.
Impact of a short course in pharmacotherapy for undergraduate medical students: an international randomised controlled study.
Lancet 1995 Dec 2;346:(8988):1454-7
HSL19748
More in-house reforms at FDA
Scrip 1995 Dec 1;
HSL1613
Coulter RH, Pinto MB.
Guilt appeals in advertising: what are their effects?
J Appl Psychol 1995 Dec;80:(6):697-705
http://content.apa.org/journals/apl/80/6/697
HSL6611
Follow-up: Sigma’s promotion of Asig (quinapril)
MaLAM Australian News 1995 Dec;3:(12):2
HSL6612
Servier claims that “3 months treatment of obesity with Adifax reduces high risk visceral fat by 31%”
MaLAM Australian News 1995 Dec;3:(12):1
HSL6613
Mansfield P, Vitry A.
Re: the promotion of Adifax (dexfenfluramine)
1995 Dec;
HSL9201
Fehring RA.
What is happening to the pharmaceutical marketplace as a result of managed care pressures?
ASHP Midyear Clinical Meeting 1995 Dec;30:
HSL9202
Cho HH, Allen SJ, Lifshin LS.
Implementation of a program for procurement of prescription drugs for indigent patients
ASHP Midyear Clinical Meeting 1995 Dec;30:
HSL6610
Estrada-claudio S.
For shame
Health Alert 1995 Nov 1-15;11:(193):7-9
HSL9191
Medication-compliance recommendations target health professionals, industry groups, patients.
Am J Health Syst Pharm. 1995 Nov 1;52:(21):2394
HSL649
Ubel PA, Arnold RM, Gramelspacher GP, Hoppe RB, Landefeld CS, Levinson W, Tierney W, Tolle SW.
Acceptance of external funds by physician organizations: issues and policy options.
J Gen Intern Med 1995 Nov;10:(11):624-30
HSL1449
Blake RL Jr, Early EK.
Patients' attitudes about gifts to physicians from pharmaceutical companies.
J Am Board Fam Pract 1995 Nov-Dec;8:(6):457-64
HSL6605
MaLAM Letter follow up—Parke-Davis’ promotion for Ponstan (mefenamic acid)
MaLAM International News 1995 Nov;13:(11):2
HSL6606
MaLAM Letter follow up—SmithKline Beecham’s promotion of Ashton & Parsons Infants’ Powder
MaLAM International News 1995 Nov;13:(11):2
HSL6607
Upjohn promotes Lincocin for tonsillitis and pharyngitis and claims Dalacin C can “in the upper respiratory tract infections fight infections, fight resistance, fight recurrence”
MaLAM International News 1995 Nov;13:(11):1
HSL6608
Hodnett J.
Targeting consumers
Medical Marketing & Media 1995 Nov;30:91-92, 94-95
HSL6609
Lexchin J, Vitry A.
Re: the promotion of Lincocin (lincomycin) and Dalacin C (clindamycin)
1995 Nov;
HSL9161
Wechsler J.
Washington report: better with FTC?
Pharmaceutical Executive 1995 Nov;15:16, 18, 20
HSL6559
Kokonis JD
The informed patient—effectively exercising healthcare choices
Ottawa: Pharmaceutical Manufacturers Association of Canada 1995 Oct 27
www.pmac-acim.org
HSL6561
Lucas PN
Providing information to consumers: the role of the brand name pharmaceutical industry
Ottawa: Pharmaceutical Manufacturers Association of Canada 1995 Oct 27
www.canadapharma.org
HSL1452
Barton SB, Walley T.
Bayer promotional publications misleading about effect of ciprofloxacin on hospital admissions.
Lancet 1995 Oct 21;346:(8982):1102
HSL6604
Wolfe SM
Testimony: FDA hearing on direct-to-consumer advertising of prescription drugs
1995 Oct 19
www.citizen.org/hrg/
HSL657
Schubert T.
Risks and benefits of calcium antagonists.
Lancet 1995 Oct 7;346:(8980):961
HSL689
Cooper RS.
Risks and benefits of calcium antagonists.
Lancet 1995 Oct 7;346:(8980):961
HSL1448
Brodie MJ, Pellock JM.
Taming the brain storms: felbamate updated.
Lancet 1995 Oct 7;346:(8980):918-9
HSL655
Shaughnessy AF, Slawson DC, Bennett JH.
Teaching information mastery: evaluating information provided by pharmaceutical representatives.
Fam Med 1995 Oct;27:(9):581-5
HSL6602
Phase II of PMAC’s Knowledge is the best medicine campaign set for Alberta launch
PMAC News 1995 Oct;1-2
HSL6603
Mintzes B.
Women and pharmaceuticals: after Beijing, what now?
HAI News 1995 Oct;(85):1-2, 12
HSL9145
Blissenbach HF.
An industry in evolution.
Med Interface 1995 Oct;8:(10):80-1,
HSL9185
Brier KL.
Pharmaceutical management strategies of industrialized countries.
Formulary 1995 Oct;30:(10):606-10,
HSL20234
Labor SL, Schommer JC, Pathak DS
Information overload with written prescription drug information
Drug Information Journal 1995 Oct;29:(4):1317-1328
http://dij.sagepub.com/content/29/4/1317.abstract
HSL666
Mabin DC.
BMJ should declare its own conflict of interest.
BMJ 1995 Sep 30;311:(7009):878-9
http://www.bmj.com/cgi/content/full/311/7009/878/b
HSL6601
Llewellyn-jones D.
It's conference time again
British Medical Journal 1995 Sep 23;311:817
http://bmj.com/cgi/content/full/311/7008/817
HSL19904
van der Heide B, Schouten E
Drug donations must be strickly regulated. Assortment of drugs causes more problems than it solves.
BMJ 1995 Sep 9;311:(7006):684
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2551445/
HSL5325
Davis DA, Thomson MA, Oxman AD, Haynes RB.
Changing physician performance. A systematic review of the effect of continuing medical education strategies
JAMA. 1995 Sep 06;274:(9):700-705
HSL676
Horton R.
Spinning the risks and benefits of calcium antagonists.
Lancet 1995 Sep 2;346:(8975):586-7
HSL677
Hodges B.
Interactions with the pharmaceutical industry: experiences and attitudes of psychiatry residents, interns and clerks.
CMAJ 1995 Sep 1;153:(5):553-9
HSL9199
Taniguchi R.
Pharmacy benefit management companies.
Am J Health Syst Pharm 1995 Sep 1;52:(17):1915-7
HSL682
Gruber W, Llewelyn J, Arras C, Lion S.
The role of the pharmaceutical industry in promoting patient education.
Patient Educ Couns 1995 Sep;26:(1-3):245-9
HSL685
Dixon AS.
Unpublishable research.
Can Fam Physician 1995 Sep;41:1443,:
HSL6599
MaLAM Australia project summary
MaLAM International News 1995 Sep-Oct;13:(9-10):1-8
HSL9136
NMA adopts new code for OTC medicine sales
New Zealand Pharmacy 1995 Sep;15:12
HSL9152
Rankin K.
Consumers reeling from Rx sticker shock
Drug Store News for the Pharmacist 1995 Sep;5:13, 15-17
HSL9164
van Trigt AM, de Jong-van den Berg LT, Voogt LM, Willems J, Tromp TF, Haaijer-Ruskamp FM.
Setting the agenda: does the medical literature set the agenda for articles about medicines in the newspapers?
Soc Sci Med 1995 Sep;41:(6):893-9
http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6VBF-3YS8D6X-31&_user=10&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000050221&_version=1&_urlVersion=0&_userid=10&md5=39fe059004d64ad38a65edd922fe376e
HSL9188
Halperin JA.
Medicine, pharmacy, and industry--a fly's eye view of health care.
Ann Pharmacother 1995 Sep;29:(9):925-33
HSL6598
Food and Drug Administration
Direct-to-consumer promotion; public hearing
1995 Aug 16
HSL1456
Arkinstall WW.
Interaction between physicians and the pharmaceutical industry.
CMAJ 1995 Aug 15;153:(4):398-9
Page 175 of 206 pages ‹ First < 173 174 175 176 177 > Last ›
